Skip to content
Companies

Rapalogix Health

Professional longevity skincare sold through dermatologists

Raised to date

$19.1M

of $25M offered across 1 Form D filing

Still open
$5.9M
Investors
28
Last filed
Jun 26, 2026

About

Rapalogix Health is a Carlsbad, California biopharma company applying cellular longevity science to skin health. It develops physician-dispensed professional skincare and a pipeline of prescription dermatology therapeutics built around selective modulation of the TORC1/mTOR pathway in skin. Its first commercial brand, Re-Q Health, launched into U.S. dermatology and aesthetic practices, and the company raised a $20 million Series A in June 2026 co-led by Woodline Partners LP and GordonMD Global Investments LP. The company was co-founded by skin longevity scientist Rahul Mehta, PhD, dermatologist Doris Day, MD, and healthcare executive Brent Saunders.

Targets the biology of skin aging through selective TORC1 pathway modulation with a patented compound (RLX-201), rather than treating surface symptoms, and sells through dermatology and aesthetic practices instead of retail.

Funding

  • EquityFiled Jun 26, 2026Form D
    $19.1M/ $25M

Product

Re-Q Pro-Longevity Face Serum

Professional skincare

The first product from Re-Q Health, Rapalogix's professional skincare brand, powered by the company's pro-longevity compound RLX-201 and available at dermatology and aesthetic practices in the United States.

  • Powered by RLX-201, a patented pro-longevity compound
  • Selective TORC1/mTOR pathway modulation in skin
  • Physician-dispensed through dermatology and aesthetic practices

Built for

Dermatology and aesthetic medicine practices in the United States, and their patients seeking science-backed anti-aging skin treatment

People on file